Amicus grabs Dimerix’s rare kidney disease drug for $30M upfront
Amicus Therapeutics has paid $30 million cash upfront to license US rights to a late-stage therapy for a rare kidney disease from the Australian biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
